Acalabrutinib Raw Material Powder

Product Name: Acalabrutinib Raw Material Powder

Brand: Henrikang

Appearance: White Powder

Storage: Cool Dry Place

Shelf Life: 2 Years

Specification​: 99% min Acalabrutinib Raw Material Powder

Test Method: HPLC

CAS: 1420477-60-6

MF: C26H23N7O2

Sample: Acalabrutinib Powder

Keywords: Acalabrutinib Powder,Acalabrutinib Raw Material Powder,Acalabrutinib Powder Supplier

Acalabrutinib Usage and Synthesis:
Acalabrutinib Powder (ACP-196) is a selective second-generation BTK inhibitor that inhibits the activation of the primary antibody signaling pathway on the surface of B cells. Acalabrutinib Powder has good target specificity, and its selectivity for BTK is 323-, 94-, 19-, 9-fold higher than that for other TEC kinase family members such as ITK, TXK, BMK and TEC. No activity on EGFR.

Pharmacokinetics of Acalabrutinib :
Acalabrutinib Powder ACP-196 is an experimental anticancer drug and a selective Bruton's tyrosine kinase (BTK) inhibitor. This kinase transmits signals from the B-cell receptor (BCR), so any inherited BTK mutation results in B-cell immunodeficiency. Therefore, BTK inhibitors targeting B cell signaling have shown great promise for the treatment of chronic lymphocytic leukemia (CLL). Acalabrutinib Powder is an experimental anticancer drug and a selective Bruton's tyrosine kinase (BTK) inhibitor. This kinase transmits signals from the B-cell receptor (BCR), so any mutation in the BTK gene results in B-cell immunodeficiency. Therefore, BTK inhibitors targeting b-cell signaling show great potential in the treatment of chronic lymphocytic leukemia (CLL).

Clinical Application of Acalabrutinib:
Acalabrutinib Powder is a second-generation small molecule Bruton's tyrosine kinase inhibitor. Acalabrutinib Powder and its metabolite ACP-5862 form a covalent bond with the 481st cysteine ​​residue in the active site of BTK, which inhibits the activity of BTK enzyme; while BTK acts as a B cell antigen receptor and cytokine receptor channel signal molecule. In B cells, the activation of BTK signaling is a channel signal necessary for B cell proliferation, transport, chemotaxis and adhesion. Acalabrutinib Powder and its metabolites selectively block the BTK pathway without destroying other molecular pathways important to platelet and immune function, thereby avoiding or reducing the occurrence of adverse reactions related to cancer therapy.